Pinnacle BioLabs sells a fecal blood test as a colon cancer screening test without FDA clearance and lacks complaint, CAPA and MDR procedures.
What happened
FDA inspected Pinnacle Labs of Tennessee (Pinnacle BioLabs) in Nashville, TN on October 27, November 1, and November 3, 2023, and also reviewed the firm's website, product insert, and brochure. FDA found the firm repackages and relabels a cleared fecal occult blood self-test and markets it for colorectal cancer screening, a new intended use the cleared device was never evaluated for. The inspection also found no complaint handling, corrective and preventive action (CAPA), design control, or medical device reporting (MDR) procedures.
What FDA found
The firm markets the test for colon cancer screening, a use the cleared device does not have, and has no premarket approval (FDA's required approval for high-risk devices) for it.
Section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)The firm did not tell FDA before putting the changed device into commercial distribution, as required by the 510(k) premarket notification process.
Section 502(o) of the Act, 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)The firm has no procedures for receiving, reviewing, and evaluating complaints, and complaint records do not include an evaluation for MDR reporting.
21 CFR 820.198(a)The firm has no procedures for corrective and preventive action (CAPA, the system for fixing problems and stopping them from recurring).
21 CFR 820.100(a)The firm has no design control procedures to show the labeled colon cancer screening use was validated.
21 CFR 820.30(a)The firm has no written procedures for medical device reporting (MDR, reporting of adverse events to FDA).
21 CFR 803.17
What FDA wants
FDA asks the firm to reply in writing within 15 business days describing the steps taken and planned to fix the violations and prevent recurrence, with documentation and a timetable for anything not yet done. If the firm believes the products are not in violation, it must send its reasoning and supporting information.
Who should pay attention
- companies private-labeling or repackaging cleared tests under new marketing claims
- clinics, health fairs and nonprofits that buy or hand out FIT screening kits
- distributors and sellers of over-the-counter screening tests
This is a summary. Read the original letter on fda.gov.